Entrada Therapeutics (TRDA) News Today $9.96 +0.06 (+0.61%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$9.96 +0.00 (+0.05%) As of 03/27/2025 04:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Entrada Therapeutics Receives UK Approval To Start Phase 1/2 Trial Of ENTR-601-45 For DMDMarch 26 at 3:41 AM | nasdaq.comEntrada receives authorization in the UK to initiate ELEVATE-45-201 studyMarch 25 at 5:38 PM | markets.businessinsider.comEntrada Therapeutics gets approval to start trial of its DMD treatment in the UKMarch 24, 2025 | msn.comEntrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 SkippingMarch 24, 2025 | globenewswire.comConnor Clark & Lunn Investment Management Ltd. Reduces Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Connor Clark & Lunn Investment Management Ltd. reduced its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 38.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 85,621 shares of the comMarch 20, 2025 | marketbeat.comEntrada Therapeutics (TRDA) Expected to Announce Earnings on WednesdayEntrada Therapeutics (NASDAQ:TRDA) will be releasing earnings before the market opens on Wednesday, March 12, Financial Modeling Prep reports.March 5, 2025 | marketbeat.comAnalysts Set Expectations for TRDA Q4 EarningsEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at Roth Capital issued their Q4 2026 earnings estimates for shares of Entrada Therapeutics in a research report issued to clients and investors on Friday, February 28th. Roth Capital analyst B. Pachaiyappan expects thatMarch 3, 2025 | marketbeat.comWhat is William Blair's Estimate for TRDA Q1 Earnings?Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at William Blair issued their Q1 2026 EPS estimates for shares of Entrada Therapeutics in a report issued on Thursday, February 27th. William Blair analyst M. Minter anticipates that the company will earn ($0.73) per shaMarch 3, 2025 | marketbeat.comEntrada Therapeutics, Inc. Just Beat EPS By 55%: Here's What Analysts Think Will Happen NextMarch 3, 2025 | finance.yahoo.comEntrada Therapeutics price target lowered to $23 from $29 at Roth MKMMarch 1, 2025 | markets.businessinsider.comEntrada Therapeutics (NASDAQ:TRDA) Releases Earnings Results, Beats Estimates By $0.69 EPSEntrada Therapeutics (NASDAQ:TRDA - Get Free Report) posted its quarterly earnings results on Thursday. The company reported $0.03 EPS for the quarter, topping analysts' consensus estimates of ($0.66) by $0.69. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%.February 28, 2025 | marketbeat.comOppenheimer Reaffirms Their Buy Rating on Entrada Therapeutics Inc (TRDA)February 28, 2025 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Entrada Therapeutics Inc (TRDA), Viridian Therapeutics (VRDN) and Definitive Healthcare Corp (DH)February 28, 2025 | markets.businessinsider.comEntrada Therapeutics Reports Fourth Quarter and Full Year 2024 Financial ResultsFebruary 27, 2025 | globenewswire.comEntrada Therapeutics (NASDAQ:TRDA) Given "Buy" Rating at HC WainwrightHC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of Entrada Therapeutics in a report on Tuesday.February 25, 2025 | marketbeat.comEntrada Shares Climb After FDA Removes Hold on Muscular Dystrophy TreatmentFebruary 25, 2025 | marketwatch.comEntrada Therapeutics, Inc.: Entrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44February 24, 2025 | finanznachrichten.deEntrada announces FDA removal of clinical hold on ENTR-601-44February 24, 2025 | markets.businessinsider.comEntrada Therapeutics Inc (TRDA) Receives a Buy from Roth MKMFebruary 24, 2025 | markets.businessinsider.comEntrada Therapeutics Announces FDA Removal of Clinical Hold on ENTR-601-44February 24, 2025 | globenewswire.comEntrada Therapeutics: Cash-Rich Innovator With Asymmetric UpsideFebruary 19, 2025 | seekingalpha.comEntrada Therapeutics, Inc. (TRDA): A Cheap Biotech Stock to Invest In NowFebruary 12, 2025 | msn.comH.C. Wainwright maintains $20 target on Entrada Therapeutics stockFebruary 4, 2025 | msn.comEntrada Therapeutics (NASDAQ:TRDA) Receives "Buy" Rating from HC WainwrightHC Wainwright restated a "buy" rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Tuesday.February 4, 2025 | marketbeat.comEntrada Therapeutics advances Duchenne treatment studyFebruary 4, 2025 | msn.comEntrada receives authorization from UK MHRA to initiate ELEVATE-44-201February 4, 2025 | markets.businessinsider.comRoth MKM Sticks to Its Buy Rating for Entrada Therapeutics Inc (TRDA)February 4, 2025 | markets.businessinsider.comEntrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular DystrophyFebruary 3, 2025 | globenewswire.comAzenta elects Entrada CEO to Board of DirectorsJanuary 31, 2025 | msn.comAzenta Announces the Election of Dipal Doshi to its Board of DirectorsJanuary 30, 2025 | prnewswire.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?January 26, 2025 | finance.yahoo.comBarclays PLC Buys 30,585 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)Barclays PLC grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 210.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 45,110 shares of the company's stock after acquiring an additionJanuary 16, 2025 | marketbeat.comEntrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6% - Here's WhyEntrada Therapeutics (NASDAQ:TRDA) Trading Down 7.6% - Time to Sell?January 10, 2025 | marketbeat.comGeode Capital Management LLC Has $9.21 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Geode Capital Management LLC boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 8.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 576,451 shares of the company's stock after buying an additional 46,512 shares duriJanuary 2, 2025 | marketbeat.comBarclays PLC Increases Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Barclays PLC lifted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 210.6% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 45,110 shares of the company's stock after acquiring an additJanuary 1, 2025 | marketbeat.comEntrada Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 18, 2024 | globenewswire.comInsider Selling: Entrada Therapeutics, Inc. (NASDAQ:TRDA) Major Shareholder Sells 22,935 Shares of StockDecember 13, 2024 | insidertrades.comXTX Topco Ltd Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)XTX Topco Ltd bought a new position in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 39,670 shares of the company's stock, valued at approximatelyDecember 13, 2024 | marketbeat.comFmr LLC Sells 85,667 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA)Fmr LLC reduced its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 4.7% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,743,498 shares of the company's stock after sellingDecember 10, 2024 | marketbeat.comJacobs Levy Equity Management Inc. Has $3.23 Million Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Jacobs Levy Equity Management Inc. boosted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 50.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 201,803 shares of the company's stock aDecember 7, 2024 | marketbeat.comJanus Henderson Group PLC Has $27.36 Million Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Janus Henderson Group PLC grew its stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 10.5% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,711,459 shares of the company's stock after purchaDecember 7, 2024 | marketbeat.comRoth MKM Initiates Coverage of Entrada Therapeutics (TRDA) with Buy RecommendationDecember 6, 2024 | msn.comEntrada Therapeutics (NASDAQ:TRDA) Now Covered by Analysts at Roth MkmRoth Mkm initiated coverage on shares of Entrada Therapeutics in a research note on Thursday. They issued a "buy" rating and a $29.00 price objective on the stock.December 6, 2024 | marketbeat.comEntrada Therapeutics, Inc. (NASDAQ:TRDA) CFO Kory James Wentworth Sells 1,000 SharesDecember 4, 2024 | insidertrades.comMassachusetts Financial Services Co. MA Makes New Investment in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Massachusetts Financial Services Co. MA acquired a new stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 69,394 shares of the company's stock, valued at appNovember 28, 2024 | marketbeat.comConnor Clark & Lunn Investment Management Ltd. Has $2.22 Million Stake in Entrada Therapeutics, Inc. (NASDAQ:TRDA)Connor Clark & Lunn Investment Management Ltd. lifted its holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) by 132.4% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 138,605 shares of tNovember 26, 2024 | marketbeat.comLos Angeles Capital Management LLC Purchases Shares of 33,932 Entrada Therapeutics, Inc. (NASDAQ:TRDA)Los Angeles Capital Management LLC acquired a new stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 33,932 shares of the company's stock, vaNovember 17, 2024 | marketbeat.comNatarajan Sethuraman Sells 1,409 Shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) StockNovember 14, 2024 | insidertrades.comQ4 EPS Estimate for Entrada Therapeutics Lifted by AnalystEntrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Stock analysts at HC Wainwright boosted their Q4 2024 earnings per share (EPS) estimates for Entrada Therapeutics in a research report issued on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company wiNovember 8, 2024 | marketbeat.comWhat is HC Wainwright's Estimate for TRDA FY2024 Earnings?Entrada Therapeutics, Inc. (NASDAQ:TRDA - Free Report) - Investment analysts at HC Wainwright boosted their FY2024 earnings estimates for shares of Entrada Therapeutics in a research report issued to clients and investors on Wednesday, November 6th. HC Wainwright analyst R. Selvaraju now forecastNovember 7, 2024 | marketbeat.com Remove Ads Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address TRDA Media Mentions By Week TRDA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. TRDA News Sentiment▼0.890.78▲Average Medical News Sentiment TRDA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. TRDA Articles This Week▼52▲TRDA Articles Average Week Remove Ads Get Entrada Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TRDA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Wave Life Sciences News Immunocore News ANI Pharmaceuticals News Dyne Therapeutics News Indivior News Amphastar Pharmaceuticals News 89bio News Adaptive Biotechnologies News ARS Pharmaceuticals News Ardelyx News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:TRDA) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredAI Boom Takes a Shocking Turn…A potentially historic moment for retirement Let's make the most of this market together. Crypto 101 Media | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Entrada Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Entrada Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
